• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

初发性急性和慢性复发阶段是Vogt-小柳-原田病的两个不同病程。

Initial-onset acute and chronic recurrent stages are two distinctive courses of Vogt-Koyanagi-Harada disease.

作者信息

Urzua Cristhian A, Herbort Carl, Valenzuela Rodrigo A, Abu El-Asrar Ahmed M, Arellanes-Garcia Lourdes, Schlaen Ariel, Yamamoto Joyce, Pavesio Carlos

机构信息

Department of Ophthalmology, Faculty of Medicine, University of Chile, Independencia, 1027, Santiago, Chile.

Laboratory of Ocular and Systemic Autoimmune Diseases, Faculty of Medicine, University of Chile, Santiago, Chile.

出版信息

J Ophthalmic Inflamm Infect. 2020 Sep 14;10(1):23. doi: 10.1186/s12348-020-00214-2.

DOI:10.1186/s12348-020-00214-2
PMID:32924094
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7487280/
Abstract

PURPOSE

To describe distinctive stages of Vogt-Koyanagi-Harada (VKH) disease: initial-onset acute versus chronic recurrent disease.

METHODS

A comprehensive literature review regarding stages and clinical presentations of VKH disease was conducted.

RESULTS

Despite a list of signs that has been described as characteristic features of early or late phases of VKH disease, the current classification -developed by an international committee and published in 2001- does not consider a distinction regarding the time from onset of disease symptoms, and specific findings observed at certain time point from the symptoms presentation and outcomes related to the stage of VKH disease. In that sense, chronic recurrent VKH disease is more refractory to treatment and is associated with a higher rate of complications. Accordingly, this subset of VKH patients has poorer functional and anatomical outcomes than patients with an initial-onset acute disease.

CONCLUSIONS

An early clear distinction of VKH phenotype [Initial-onset acute versus chronic recurrent disease] should be considered in each clinical scenario, evaluating the delay in diagnosis and the clinical presentation, since it may help clinicians to perform a correct disease prognosis categorization and thus to make treatment decisions in terms of potential refractoriness or expected clinical outcomes.

摘要

目的

描述葡萄膜大脑炎(VKH)疾病的不同阶段:初发性急性疾病与慢性复发性疾病。

方法

对VKH疾病的阶段和临床表现进行了全面的文献综述。

结果

尽管有一系列体征被描述为VKH疾病早期或晚期的特征,但由一个国际委员会制定并于2001年发表的现行分类并未考虑疾病症状出现时间的差异,以及在症状出现后的特定时间点观察到的具体发现和与VKH疾病阶段相关的结果。从这个意义上说,慢性复发性VKH疾病对治疗更具难治性,且并发症发生率更高。因此,与初发性急性疾病患者相比,这部分VKH患者的功能和解剖学预后更差。

结论

在每种临床情况下,应考虑早期明确区分VKH表型[初发性急性疾病与慢性复发性疾病],评估诊断延迟和临床表现,因为这可能有助于临床医生进行正确的疾病预后分类,从而根据潜在的难治性或预期的临床结果做出治疗决策。

相似文献

1
Initial-onset acute and chronic recurrent stages are two distinctive courses of Vogt-Koyanagi-Harada disease.初发性急性和慢性复发阶段是Vogt-小柳-原田病的两个不同病程。
J Ophthalmic Inflamm Infect. 2020 Sep 14;10(1):23. doi: 10.1186/s12348-020-00214-2.
2
Clinical and Transcriptional Profiles Reveal the Treatment Effect of Adalimumab in Patients with Initial-Onset and Recurrent Vogt-Koyanagi-Harada Disease.临床和转录特征揭示阿达木单抗对初发性和复发性Vogt-小柳原田病患者的治疗效果。
Ocul Immunol Inflamm. 2025 Apr;33(3):347-357. doi: 10.1080/09273948.2024.2346814. Epub 2024 May 6.
3
Different MicroRNA profiles in Peripheral Blood mononuclear cells from patients with initial-onset and recurrent vogt-Koyanagi-Harada Disease.初发和复发型Vogt-小柳-原田病患者外周血单个核细胞中的不同微小RNA谱
Mol Biol Rep. 2022 Dec;49(12):11421-11431. doi: 10.1007/s11033-022-07753-y. Epub 2022 Aug 21.
4
Clinical spectrum and management options in Vogt-Koyanagi-Harada disease.Vogt-小柳-原田病的临床谱及治疗选择
Clin Ophthalmol. 2017 Aug 7;11:1399-1406. doi: 10.2147/OPTH.S134977. eCollection 2017.
5
Prognostic factors for clinical outcomes in patients with Vogt-Koyanagi-Harada disease treated with high-dose corticosteroids.大剂量皮质类固醇治疗 Vogt-Koyanagi-Harada 病患者的临床转归的预后因素。
Acta Ophthalmol. 2013 Sep;91(6):e486-93. doi: 10.1111/aos.12127. Epub 2013 Apr 10.
6
Catching the therapeutic window of opportunity in early initial-onset Vogt-Koyanagi-Harada uveitis can cure the disease.在初发性Vogt-小柳-原田葡萄膜炎早期抓住治疗时机可治愈该病。
Int Ophthalmol. 2019 Jun;39(6):1419-1425. doi: 10.1007/s10792-018-0949-4. Epub 2018 Jun 11.
7
The Incidence and Presentation Features of Glaucoma in Vogt-Koyanagi-Harada Syndrome: A Systematic Review and Meta-Analysis.Vogt-小柳原田综合征的青光眼发病率和表现特征:系统评价和荟萃分析。
Ophthalmol Glaucoma. 2024 Nov-Dec;7(6):587-601. doi: 10.1016/j.ogla.2024.06.005. Epub 2024 Jul 2.
8
Vogt-koyanagi-harada syndrome.伏格特-小柳-原田综合征
Curr Eye Res. 2008 Jul;33(7):517-23. doi: 10.1080/02713680802233968.
9
Longitudinal quantification of aqueous flare and cells in Vogt-Koyanagi-Harada disease.Vogt-小柳-原田病中房水闪光和细胞的纵向定量分析。
Br J Ophthalmol. 2008 Feb;92(2):182-5. doi: 10.1136/bjo.2007.128967. Epub 2007 Oct 26.
10
Vogt-Koyanagi-Harada is a Curable Autoimmune Disease: Early Diagnosis and Immediate Dual Steroidal and Non-Steroidal Immunosuppression are Crucial Prerequisites.伏格特-小柳-原田病是一种可治愈的自身免疫性疾病:早期诊断以及立即进行双甾体和非甾体免疫抑制是关键前提条件。
J Curr Ophthalmol. 2020 Dec 12;32(4):310-314. doi: 10.4103/JOCO.JOCO_190_20. eCollection 2020 Oct-Dec.

引用本文的文献

1
Retrospective analysis of Vogt-Koyanagi-Harada's recurrence within a case series of nineteen patients followed between 2003 and 2018 in an academic center.对19例患者在2003年至2018年期间于某学术中心进行随访的病例系列中Vogt-小柳-原田病复发情况的回顾性分析。
J Ophthalmic Inflamm Infect. 2025 Jul 1;15(1):50. doi: 10.1186/s12348-025-00498-2.
2
Revising the role of cerebrospinal fluid pleocytosis as a diagnostic criterion in Vogt-Koyanagi-Harada disease.重新审视脑脊液细胞增多症在Vogt-小柳-原田病诊断标准中的作用。
Eye (Lond). 2025 Jun 19. doi: 10.1038/s41433-025-03892-1.
3
Vogt-Koyanagi-Harada Syndrome from Dermatological Perspective: A Case Report.从皮肤科角度看葡萄膜大脑炎综合征:一例报告
Indian Dermatol Online J. 2025 Jan 28;16(3):484-487. doi: 10.4103/idoj.idoj_301_24. eCollection 2025 May-Jun.
4
Vogt-Koyanagi-Harada-like disease secondary to anticancer treatment: a multicentre case series.抗癌治疗继发的类Vogt-小柳-原田病:一项多中心病例系列研究
Eye (Lond). 2025 Mar 13. doi: 10.1038/s41433-025-03720-6.
5
Inadequacies in uveitis: misnomers, incongruencies, persistence of obsolete terminologies & inappropriate guidelines, treatment inadequacies, and misinterpretations.葡萄膜炎的不足之处:名称不当、不一致、过时术语的持续存在及不恰当的指南、治疗不足和误解。
J Ophthalmic Inflamm Infect. 2025 Mar 6;15(1):19. doi: 10.1186/s12348-025-00470-0.
6
Disease processes and terminology cannot be determined by opinion polls but have to be based on objective facts: The "white dots" case.疾病过程和术语不能由民意调查来确定,而必须基于客观事实:“白点”病例。
Saudi J Ophthalmol. 2024 Mar 29;38(1):92-94. doi: 10.4103/sjopt.sjopt_67_24. eCollection 2024 Jan-Mar.
7
Vogt-Koyanagi-Harada Disease and COVID.伏格特-小柳-原田病与新冠病毒
J Clin Med. 2023 Sep 27;12(19):6242. doi: 10.3390/jcm12196242.
8
Incidence and Risk Factors of Recurrent Anterior Uveitis in Initial Acute-Onset Vogt-Koyanagi-Harada Disease.初发急性发作性 Vogt-小柳原田病患者中复发性前葡萄膜炎的发生率及危险因素。
Korean J Ophthalmol. 2023 Aug;37(4):299-306. doi: 10.3341/kjo.2023.0017. Epub 2023 Jul 3.
9
Optical Coherence Tomography in Inflammatory and Neoplastic Lesions Deforming the Choroidal Profile.光学相干断层扫描在使脉络膜轮廓变形的炎症性和肿瘤性病变中的应用
Diagnostics (Basel). 2023 Jun 7;13(12):1991. doi: 10.3390/diagnostics13121991.
10
Classification of Vogt-Koyanagi-Harada disease using feature selection and classification based on wide-field swept-source optical coherence tomography angiography.基于超广角扫频源光学相干断层扫描血管造影术,利用特征选择和分类对Vogt-小柳-原田病进行分类
Front Bioeng Biotechnol. 2023 May 2;11:1086347. doi: 10.3389/fbioe.2023.1086347. eCollection 2023.

本文引用的文献

1
Ultrabiomicroscopic Findings in Acute Uveitic, Convalescent and Chronic Recurrent Stage of Vogt-Koyanagi-Harada Syndrome.Vogt-小柳-原田综合征急性葡萄膜炎、恢复期和慢性复发性阶段的超微结构发现。
Ocul Immunol Inflamm. 2020 May 18;28(4):626-631. doi: 10.1080/09273948.2019.1609527. Epub 2019 Jul 17.
2
Update on the epidemiology, risk factors and disease outcomes of Juvenile idiopathic arthritis.幼年特发性关节炎的流行病学、危险因素和疾病转归的最新进展。
Best Pract Res Clin Rheumatol. 2018 Apr;32(2):206-222. doi: 10.1016/j.berh.2018.10.004. Epub 2018 Nov 19.
3
Development and Evaluation of Diagnostic Criteria for Vogt-Koyanagi-Harada Disease.Vogt-Koyanagi-Harada 病诊断标准的制定与评估。
JAMA Ophthalmol. 2018 Sep 1;136(9):1025-1031. doi: 10.1001/jamaophthalmol.2018.2664.
4
Improving the Diagnostic Criteria for Vogt-Koyanagi-Harada Disease.改进Vogt-小柳-原田病的诊断标准。
JAMA Ophthalmol. 2018 Sep 1;136(9):1032-1033. doi: 10.1001/jamaophthalmol.2018.2657.
5
Catching the therapeutic window of opportunity in early initial-onset Vogt-Koyanagi-Harada uveitis can cure the disease.在初发性Vogt-小柳-原田葡萄膜炎早期抓住治疗时机可治愈该病。
Int Ophthalmol. 2019 Jun;39(6):1419-1425. doi: 10.1007/s10792-018-0949-4. Epub 2018 Jun 11.
6
Clinical features and visual outcomes of 111 patients with new-onset acute Vogt-Koyanagi-Harada disease treated with pulse intravenous corticosteroids.111 例新发急性 Vogt-小柳原田病患者采用脉冲静脉内皮质类固醇治疗的临床特征和视力结果。
Br J Ophthalmol. 2019 Feb;103(2):274-278. doi: 10.1136/bjophthalmol-2017-311691. Epub 2018 Apr 17.
7
Corticotherapy vs. Corticotherapy Plus Immunosuppressive Therapy in Acute Vogt-Koyanagi-Harada Disease.急性Vogt-小柳-原田病中皮质类固醇疗法与皮质类固醇疗法联合免疫抑制疗法的比较
Arch Soc Esp Oftalmol (Engl Ed). 2018 May;93(5):225-230. doi: 10.1016/j.oftal.2017.09.010. Epub 2017 Dec 16.
8
Interobserver Agreement Among Uveitis Experts on Uveitic Diagnoses: The Standardization of Uveitis Nomenclature Experience.葡萄膜炎专家间对葡萄膜炎诊断的一致性:葡萄膜炎命名标准经验。
Am J Ophthalmol. 2018 Feb;186:19-24. doi: 10.1016/j.ajo.2017.10.028. Epub 2017 Nov 6.
9
Choroidal and Retinal Anatomical Responses Following Systemic Corticosteroid Therapy in Vogt-Koyanagi-Harada Disease Using Swept-Source Optical Coherence Tomography.应用扫频源光学相干断层扫描观察系统性皮质类固醇治疗 Vogt-小柳原田病后的脉络膜和视网膜解剖学反应。
Ocul Immunol Inflamm. 2019;27(2):235-243. doi: 10.1080/09273948.2017.1332231. Epub 2017 Jul 12.
10
Evaluation of the Glucocorticoid Receptor as a Biomarker of Treatment Response in Vogt-Koyanagi-Harada Disease.评估糖皮质激素受体作为伏格特-小柳-原田病治疗反应生物标志物的作用
Invest Ophthalmol Vis Sci. 2017 Feb 1;58(2):974-980. doi: 10.1167/iovs.16-20783.